PCR Detection of MRSA in as little as 47 Minutes*

Xpert® MRSA NxG

 
 

Methicillin-resistant Staphylococcus aureus (MRSA) remains one of the most prevalent challenges for hospital systems, with around 5% of all healthcare-associated infections (HAIs) being caused by MRSA.1

 

MRSA are resistant to several antibiotics and can spread easily in healthcare and community-based setting.2

 

Early identification of patients colonised or infected with MRSA can help minimise transmission and inform early interventions to prevent invasive infections.2

 

“Fast screening of trauma on arrival enables admission directly to the elective ward if MRSA negative, maximising bed occupancy and minimising the cancellation of elective surgeries. It also speeds up progression along the care pathway, improving the patient experience, and has driven down the associated breaches of the 52-week referral to treatment (RTT) target.”

Gillian Hewlett

Microbiology Laboratory Manager and Head Biomedical Scientist

Sue Evans

Matron, Orthopaedic Ward

 

Torbay and South Devon NHS Foundation Trust, UK

 

Who Should be Tested?

It is recommended that NHS hospitals streamline patient screening to the following:3

  • All patients admitted to high-risk units, e.g., ICU, orthopaedics/trauma, renal/dialysis, cardiothoracic surgery, haematology/oncology/bone, etc.
  • All patients previously identified as colonised with or infected by MRSA
 

Why Test with Fast PCR?

Fast and accurate PCR diagnostics with Cepheid’s GeneXpert® system and Xpert® MRSA NxG test provide standardised, on-demand, and actionable results in 47 minutes*, enabling healthcare systems with the potential to enhance clinical efficiency, enable optimised infection control and improve patient flow through the hospital.4 

 

MRSA is an evolving threat, and with the emergence of new strains (e.g., mecC), rapid and importantly sensitive detection have become even more important.5,6

 

Xpert® MRSA NxG

Detection of MRSA, including expanded coverage demonstrated using an extensive library of over 195 MRSA strains from around the world, and updated primers for both mecA and mecC strains to reduce false-positive results due to “empty cassettes”, in as soon as 47 minutes.7 

 

Impact:

  • Improved bed & isolation management6
  • Reduced MRSA infection rates8
  • Decreased overall hospital costs9

GeneXpert® Systems

Our GeneXpert® family of systems have set a new standard in workflow flexibility, 24/7 accuracy, and user-friendly design.

 

Our engaging platform delivers:

  • On-demand and random-access walkway testing
  • Unique scalability and flexible design from 2-80 modules
  • Simplified workflow
  • Easy to maintain
  • Full connectivity

 

>30 CE-IVD Tests, One GeneXpert System for Consolidated AMR PCR Testing

 

COVID-19, Flu & RSV

Results in 36 minutes

Carbapenem-resistant Bacteria

Results in 50 minutes

C. difficile

Results in 43 minutes

Group B Streptoccoccus

Results in 56 minutes

MRSA

Results in 47 minutes*

TB & Resistance

Results in <90 minutes

Norovirus

Results in 60 minutes^

Vancomycin-resistant Bacteria

Results in 48 minutes

 

Choose Cepheid as your Trusted Diagnostics NHS Partner Today

Over the last 28 years, Cepheid has partnered with many hospitals, clinics, and laboratories around the world with more than 50,000 systems installed and millions of tests performed, including ~2 million PCR tests delivered to NHS hospitals each year10, changing the lives of patients.

 

With our solutions, your healthcare organisation can potentially reduce costs, streamline operations, and maximise productivity while prioritising patient health.

 

Download MRSA Infographic

Speak to our experts about your stewardship and outbreak prevention plan

I would like to be part of the Cepheid Community and I understand and consent to receive information about products and services, invitations to virtual and in-person events such as workshops and webinars and educational content from Cepheid and similar information from Cepheid’s affiliates and representatives.

*required fields
Cepheid respects your privacy, and values the relationship with our customers, partners, and associates. Your personal data may be processed by Cepheid, its affiliates, representatives and other Danaher companies for business and marketing purposes. You can review Cepheid Privacy Policy online for additional information on your rights and how we use and share personal data we collect on our websites and other channels. Your consent to receiving Cepheid news can be withdrawn at any time. Building a relationship of trust is important to us and we will happily help with any questions on your personal data processing addressed to Privacy.officer@cepheid.com

CE-IVD. In Vitro Diagnostic Medical Device. May not be available in all countries.

* For positive MRSA results with early assay termination. Otherwise, full runtime is 70 minutes.
^ For positive Norovirus results with early assay termination. Otherwise, full runtime is 90 minutes.

1. Hübner C, et al. Impact of different diagnostic technologies for MRSA admission screening in hospitals – a decision tree analysis. Antimicrobial Resistance and Infection Control. 2015 Dec;4(50).

2. Yarbrough M, et al. Multicenter evaluation of the Xpert MRSA NxG assay for detection of methicillin-resistant Staphylococcus aureus in Nasal Swabs. J Clin Microbiol. 2017 Dec;56(1).

3. DHSC. MRSA Screening Guidance. 2014. https://www.gov.uk/government/publications/how-to-approach-mrsa-screening 

4. Clinical Services Journal. Feb 2022. POC Testing of Trauma Patients for MRSA.

https://www.clinicalservicesjournal.com/story/37642/poc-testing-of-trauma-patients-for-mrsa

5. Bal AM, et al. Genomic insights into the emergence and spread of international clones of healthcare-, community- and livestock-associated methicillin-resistant Staphylococcus aureus: Blurring of the traditional definitions. J Glob Antimicrob Resist. 2016 6:95-101.

6. Wassenberg et al. Costs and benefits of rapid screening of methicillin-resistant Staphylococcus aureus carriage in intensive care units: a prospective multicenter study. Crit Care. 2012 16(1):R22.

7. Xpert MRSA NxG Package Insert.

8. Evans ME, et al. Active Surveillance and Contact Precautions for Preventing Methicillin-Resistant Staphylococcus aureus Healthcare-Associated Infections During the COVID-19 Pandemic. Clin Infect Dis. 2023 Nov 17;77(10):1381-1386. doi: 10.1093/cid/ciad388. PMID: 37390613.

9. Tübbicke A, et al. Cost comparison of MRSA screening and management—a decision tree analysis. BMC Health Services Research. 2013 Dec;12:438.

10. 2023 Internal data analysis actual 1.9.

About Cepheid

Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid's broad test portfolio spans respiratory infections, blood virology, women's and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company's solutions deliver actionable results where they are needed most from central laboratories and hospitals to near patient settings.

For more information, visit www.cepheid.com

© 2025 Cepheid. All Rights Reserved.